Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor (AChR) ...

Topline phase 3 results show that the novel nanobody gefurulimab is safe and effective for AChR-antibody-positive myasthenia ...

Results from the global PREVAIL Phase 3 trial showed that gefurulimab met its primary endpoint, demonstrating a statistically significant and ...

AZ is already a major presence in gMG treatment with its current antibody-based anti-C5 drugs – Soliris (eculizumab) and ...

Gefurulimab showed significant improvements in MG-ADL scores in the phase 3 PREVAIL study for anti-AChR antibody-positive gMG patients. The treatment was well tolerated, with a safety profile ...

AstraZeneca announced promising trial results for gefurulimab, a potential new treatment for generalized myasthenia gravis, marking a significant advancement in their product line. Last week, the ...

Positive high-level results from a global, randomised, double-blind, placebo-controlled phase III trial in adults with anti-acetylcholine receptor (AChR) antibody-positive (Ab+) generalised myasthenia ...

Astrazeneca plc reported positive “high-level” results from a global, randomized, double-blind, placebo-controlled phase III trial with once-weekly, self-administered gefurulimab in adults with ...

PREVAIL phase III trial of gefurulimab meets its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement from baseline in MG-ADL ...

AstraZeneca’s gefurulimab met its primary endpoint, but has not managed to best the efficacy demonstrated by its rival therapies in a late-stage generalised myasthenia gravis (gMG) trial. In the Phase ...

Dear stakeholders, For information, NICE has decided to defer the single technology appraisal of gefurulimab for treatment of antibody-positive generalised myasthenia gravis. This is due to a request ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. An experimental drug from AstraZeneca succeeded in a ...